Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
May 11, 2023
Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022 Launched Betaine Anhydrous Management to hold conference call today at 4:30pm ET DEER PARK, Ill. , May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an
May 10, 2023
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* -- -- Product is now available exclusively through Optime Care -- DEER PARK, Ill. , May 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company
May 3, 2023
DEER PARK, Ill. , May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2023 financial results on Thursday, May 11,